7,889 reports of this reaction
23.8% of all CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE reports
#1 most reported adverse reaction
BREAST CANCER is the #1 most commonly reported adverse reaction for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 7,889 FDA adverse event reports linking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE to BREAST CANCER. This represents approximately 23.8% of all 33,191 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is a frequently reported adverse event for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, accounting for a significant proportion of all reports.
In addition to breast cancer, the following adverse reactions have been reported for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 7,889 FDA reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 23.8% of all adverse event reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, making it one of the most commonly reported side effect.
If you experience breast cancer while taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.